

SUPPLEMENTARY MATERIALS

Title: Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis

Authors: Jihoon Lim MS, Imen Farhat MSc, Antonios Douros MD PhD, Soukaina Ouizzane BSc, Dimitra Panagiotoglou PhD

Table S1. Search strategy

Database	Algorithm
MEDLINE	<ol style="list-style-type: none"> 1. exp opioid-related disorders/ 2. ((drug OR substance OR opioid* OR opiat*) adj3 (disorder* OR addict* OR abuse* OR depend*)),ti,ab,kf. 3. 1 OR 2 4. exp buprenorphine/ OR buprenorphine.ti,ab,kf. 5. exp methadone/ OR methadone.ti,ab,kf. 6. 4 OR 5 7. ((opioid OR drug) adj2 (overdose* OR mortal* OR death* OR fatal* OR poison*)),ti,ab,kf. 8. 3 AND 6 AND 7 9. exp animals/ not humans.sh. 10. 8 NOT 9 11. limit 10 to yr="1978 -Current"
EMBASE	<ol style="list-style-type: none"> 1. exp addiction/ 2. exp drug abuse/ 3. ((drug OR substance OR opioid* OR opiat*) adj3 (disorder* OR addict* OR abuse* OR depend*)),ab,ti. 4. 1 OR 2 OR 3 5. exp buprenorphine/ OR buprenorphine.ab,ti. 6. exp methadone/ OR methadone.ab,ti. 7. 5 OR 6 8. ((opioid OR drug) adj2 (overdose* OR mortal* OR death* OR fatal* OR poison*)),ti,ab,kw,dj. 9. 4 AND 7 AND 8 10. limit 9 to (human AND embase AND yr="1978 -Current")
PsycINFO	<ol style="list-style-type: none"> 1. exp addiction/ 2. exp drug abuse/ 3. ((drug OR substance OR opioid* OR opiat*) adj3 (disorder* OR addict* OR abuse* OR depend*)),ti,ab,id. 4. 1 OR 2 OR 3 5. exp buprenorphine/ OR buprenorphine.ti,ab,id. 6. exp methadone/ OR methadone.ti,ab,id. 7. 5 OR 6 8. ((opioid OR drug) adj2 (overdose* OR mortal* OR death* OR fatal* OR poison*)),ti,ab,id. 9. 4 AND 7 AND 8 10. exp animals/ not humans.sh. 11. 9 NOT 10 12. Limit 11 to yr="1978 -Current"
Web of Science	<ol style="list-style-type: none"> 1. TS=(addiction) 2. TS=(drug abuse) 3. TS=((drug OR substance OR opioid* OR opiat*) NEAR/3 (disorder* OR addict* OR abuse* OR depend*)) 4. 1 OR 2 OR 3 5. TS=(buprenorphine) 6. TS=(methadone) 7. 5 OR 6 8. TS=((opioid OR drug) NEAR/2 (overdose* OR mortal* OR death* OR fatal* OR poison*)) 9. 4 AND 7 AND 8 10. TS=(animal* not (human* or patient*)) 11. 9 NOT 10 12. PY=(1978-2021) 13. 11 AND 12

Table S2. Articles selected for full-text review and reasons for exclusion

Last Name of First Author (Publication Year)	Article Title	Reason(s) for exclusion
Alderbergenov et al. (2022)	Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England	No measure of association calculated
Alexandridis et al. (2019)	Associations between implementation of Project Lazarus and opioid analgesic dispensing and buprenorphine utilization in North Carolina, 2009-2014	Outcome outside the scope of study
Ali et al. (2019)	Opioid Use Disorder and Prescribed Opioid Regimens: Evidence from Commercial and Medicaid Claims, 2005-2015	Outcome outside the scope of study
Alinski et al. (2020)	Receipt of Addiction Treatment after Opioid Overdose among Medicaid-Enrolled Adolescents and Young Adults	Outcome outside the scope of study
Bagley et al. (2020)	Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose	Outcome outside the scope of study
Bauer et al. (2008)	Mortality in opioid-maintained patients after release from an addiction clinic	No measure of association calculated
Bech et al. (2019)	Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study	Included
Bell et al. (2009)	Comparing overdose mortality associated with methadone and buprenorphine treatment	Included
Bhatraju et al. (2021)	Mortality in an opioid treatment program	No measure of association calculated
Buresh et al. (2021)	Treatment of opioid use disorder in primary care	No measure of association calculated
Burns et al. (2022)	Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study	No direct comparison between buprenorphine and methadone
Caplehorn et al. (1999)	Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved	No direct comparison between buprenorphine and methadone
Care et al. (2020)	Trends in severe opioid-related poisonings and fatalities reported to the Paris poison control center - a 10-year retrospective observational study	No measure of association calculated
Clausen et al. (2009)	Mortality among opiate users: opioid maintenance therapy, age and causes of death	No direct comparison between buprenorphine and methadone
Cornish et al. (2010)	Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database	No direct comparison between buprenorphine and methadone
Cousins et al. (2020)	Do interruptions to the continuity of methadone maintenance treatment (MMT) in specialist addiction settings increase the risk of drug-related poisoning (DRP) deaths? A retrospective cohort study	No direct comparison between buprenorphine and methadone
Cousins et al. (2011)	Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study	No direct comparison between buprenorphine and methadone
Dasgupta et al. (2010)	Post-marketing Surveillance of Methadone and Buprenorphine in the United States	Outcome outside the scope of study

Degenhardt et al. (2009)	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved	No measure of association calculated
Dermengiu et al. (2013)	Drug related deaths between 2008 and 2011. A retrospective study in 32 Romanian counties	No measure of association calculated
Dermengiu et al. (2011)	Drugs of abuse identified in the National Institute of Legal Medicine Mina Minovici Bucharest 2010	No measure of association calculated
Eastwood et al. (2017)	Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England	Outcome outside the scope of study
Faggiano et al. (2020)	Opioid overdose risk during and after drug treatment for heroin dependence: An incidence density case-control study nested in the vedette cohort	No direct comparison between buprenorphine and methadone
Fernandez-Calderon et al. (2017)	Drug-induced deaths in Southern Spain: profiles and associated characteristics	Outcome outside the scope of study
Fine et al. (2021)	Office-based addiction treatment retention and mortality among people experiencing homelessness	Outcome outside the scope of study
Fountain et al. (2019)	Deaths by poisoning in New Zealand, 2008-2013	No measure of association calculated
Fugelstad et al. (2019)	Opioid-related deaths and previous care for drug use and pain relief in Sweden	No measure of association calculated
Fulton-Kehoe et al. (2015)	Opioid Poisonings in Washington State Medicaid: Trends, Dosing, and Guidelines	No measure of association calculated
Gibson et al. (2007)	Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records	No direct comparison between buprenorphine and methadone
Glanz et al. (2022)	The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment	No direct comparison between buprenorphine and methadone
Gomes et al. (2022)	Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study	Outcome outside the scope of study
Gottlieb et al. (2022)	A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder	No measure of association provided
Hakkinen et al. (2012)	Comparison of fatal poisonings by prescription opioids	Outcome outside the scope of study
Hall et al. (2000)	Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995	No measure of association calculated
Hall et al. (2008)	Patterns of abuse among unintentional pharmaceutical overdose fatalities	Outcome outside the scope of study
Hallowell et al. (2021)	History of Methadone and Buprenorphine Opioid Agonist Therapy Among People Who Died of an Accidental Opioid-Involved Overdose: Rhode Island, January 1, 2018–June 30, 2020	No measure of association calculated
Hammersley et al. (1995)	Drugs associated with drug-related deaths in Edinburgh and Glasgow, November 1990 to October 1992	No measure of association calculated
Handanagic et al. (2019)	Overdose mortality rates in Croatia and factors associated with self-reported drug overdose among persons who inject drugs in three Croatian cities	Outcome outside the scope of study
Handley et al. (2014)	Drugs and other chemicals involved in fatal poisoning in England and Wales during 2000-2011	No measure of association calculated
Hickman et al. (2018)	The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom	Included

Huang et al. (2013)	Factors associated with mortality among heroin users after seeking treatment with methadone: A population-based cohort study in Taiwan	No direct comparison between buprenorphine and methadone
Iwanicki et al. (2018)	Consistency Between Opioid-Related Mortality Trends Derived from Poison Center and National Vital Statistics System, United States, 2006-2016	No measure of association calculated
Jones et al. (2022)	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study	Included
Jones et al. (2023)	Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic	No direct comparison between buprenorphine and methadone
Kalkman et al. (2019)	Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study	No direct comparison between buprenorphine and methadone
Karmali et al. (2020)	The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose	Outcome outside the scope of study
Kelty et al. (2017)	Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone	No direct comparison between buprenorphine and methadone
Kelty et al. (2018)	Morbidity and mortality in opioid dependent patients after entering an opioid pharmacotherapy compared with a cohort of non-dependent controls	No direct comparison between buprenorphine and methadone
Kimber et al. (2015)	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: A retrospective cohort study	Included
Krawczyk et al. (2020)	Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services	No direct comparison between buprenorphine and methadone
Krawczyk et al. (2020)	Opioid agonist treatment is highly protective against overdose death among a U.S. statewide population of justice-involved adults	No direct comparison between buprenorphine and methadone
Larney et al. (2014)	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study	No direct comparison between buprenorphine and methadone
Larney et al. (2023)	Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17	Included
Larochelle et al. (2018)	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association with Mortality A Cohort Study	No direct comparison between buprenorphine and methadone
Lev et al. (2015)	Methadone related deaths compared to all prescription related deaths	No measure of association calculated
Lewer et al. (2020)	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia	Outcome outside the scope of study
Lim et al. (2022)	Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-2017	No direct comparison between buprenorphine and methadone
Lin et al. (2019)	Changing Trends in Opioid Overdose Deaths and Prescription Opioid Receipt Among Veterans	No direct comparison between buprenorphine and methadone

Marsden et al. (2017)	Does exposure to opioid substitution treatment in prison reduce the risk of death after release? A national prospective observational study in England	No direct comparison between buprenorphine and methadone
Marteau et al. (2015)	The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales	Included
Megarbane et al. (2010)	Prospective comparative assessment of buprenorphine overdose with heroin and methadone: Clinical characteristics and response to antidotal treatment	No measure of association calculated
Mintz et al. (2022)	Associations between Stimulant Prescriptions and Drug-related Poisoning Risk among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder	No direct comparison between buprenorphine and methadone
Morgan et al. (2020)	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting	Outcome outside the scope of study
Moe et al. (2021)	Death after emergency department visits for opioid overdose in British Columbia: a retrospective cohort analysis	Outcome outside the scope of study
Pearce et al. (2020)	Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study	No direct comparison between buprenorphine and methadone
Pierce et al. (2016)	Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England	No direct comparison between buprenorphine and methadone
Qeadan et al. (2022)	Epidemiological trends in opioid-only and opioid/polysubstance-related death rates among American Indian/Alaska Native populations from 1999 to 2019: a retrospective longitudinal ecological study	No measure of association calculated
Rezza et al. (1992)	Estimating the trend of the epidemic of drug use in Italy, 1985-89	No measure of association calculated
Shastry et al. (2022)	Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity	No direct comparison between buprenorphine and methadone
Skeie et al. (2022)	Mortality, Causes of Death, and Predictors of Death among Patients On and Off Opioid Agonist Treatment: Results from a 19-Year Cohort Study	No direct comparison between buprenorphine and methadone
Soyka et al. (2006)	One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy - A nationally representative cohort study in 2694 patients	No measure of association calculated
Soyka et al. (2006)	Fatal poisoning in methadone and buprenorphine treated patients - Are there differences?	No measure of association calculated
Sun et al. (2022)	Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States	No direct comparison between buprenorphine and methadone
Thylstrup et al. (2020)	Incidence and predictors of drug overdoses among a cohort of >10,000 patients treated for substance use disorder	No direct comparison between buprenorphine and methadone
Vakkalanka et al. (2021)	Association between buprenorphine for opioid use disorder and mortality risk	No direct comparison between buprenorphine and methadone
Victor et al. (2021)	Buprenorphine Treatment Intake and Critical Encounters following a Nonfatal Opioid Overdose	No direct comparison between buprenorphine and methadone
Wakeman et al. (2020)	Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder	No direct comparison between buprenorphine and methadone

Walley et al. (2019)	The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015	No measure of association calculated
Walley et al. (2020)	Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis	No direct comparison between buprenorphine and methadone
Wikner et al. (2014)	Opioid-related mortality and filled prescriptions for buprenorphine and methadone	No measure of association calculated
Wysowski (2007)	Surveillance of prescription drug-related mortality using death certificate data	No measure of association calculated
Zador et al. (2000)	Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995	No measure of association calculated

Table S3. Data extraction form

Variable	Description
First_author	Last name of the first author
Journal	Journal where the article was published
Publication_year	Year in which the article was published
Study Characteristics	
Study_design	Study design (e.g., cohort study, or case-control study)
Setting	Country
Study_period	Study period
Data_source	Data source
Mean_fup_duration	Mean follow-up duration
Follow_up	Patient follow-up and censoring definition
Exposure_def	Exposure definition (e.g., intention-to-treat, as-treated, and time-varying)
Outcome_def	Outcome definition (e.g., ICD-9/10, DSM-IV, etc.)
Eligibility	Key inclusion and exclusion criteria
N_total	Total number of patients
N_bup	Number and % of treatment episodes with buprenorphine
N_met	Number and % of treatment episodes with methadone
Patient Characteristics at Baseline	
Mean_age	Mean age of patients
Male	% of male patients
Psychiatric	% of patients with any or specific psychiatric or mental health disorders
Effect Measures and Corresponding 95% CI	
Exposure_group	Exposure group
Reference_group	Reference group
Outcome	Specific outcome investigated
Occasion	Effect measure during maintenance treatment, after treatment discontinuation, or overall
N_deaths_bup	Number of buprenorphine-related deaths
PY_bup	Person-years for the buprenorphine group
N_deaths_met	Number of methadone-related deaths
PY_met	Person-years for the methadone group
Model	Statistical model employed
Confounders	Confounders included in the regression model
Confounding_ctrl	Techniques employed to control for confounding
Effect_measure	Type of effect measure reported (HR, OR, or IRR)
Estimate	Adjusted estimate of association
LCI95	Lower limit of the 95% CI
UCI95	Upper limit of the 95% CI

Table S4. Full data extraction

Description	Study 1	Study 2	Study 3	Study 4	Study 5	Study 6	Study 7
Last name of the first author	Bech	Bell	Hickman	Jones	Kimber	Larney	Marteau
Journal where the article was published	BMC Health Services Research	Drug and Alcohol Dependence	Addiction	Drug and Alcohol Dependence	Lancet Psychiatry	Addiction	BMJ Open
Publication year	2019	2009	2018	2022	2015	2023	2015
Study design	Retrospective registry study	Retrospective data linkage study	Retrospective cohort study	Retrospective cohort study	Retrospective cohort study	Retrospective cohort study	Retrospective administrative data study
Country	Norway	New South Wales, Australia	UK	New South Wales, Australia	New South Wales, Australia	New South Wales, Australia	England and Wales
Study period	January 1, 2014-December 31, 2015	April 1, 2006-December 31, 2006	1998-2014	2002-2017	2001-2010	2002-2017	2007-2012
Data source	(a) Norwegian Cause of Death Registry (b) Norwegian Patient Registry	Pharmaceutical Drugs of Addiction System	(a) Clinical Practice Research Datalink (b) Office for National Statistics (mortality data)	Electronic Reporting and Recording of Controlled Drugs (formerly Pharmaceutical Drugs of Addiction System)	Pharmaceutical Drugs of Addiction System	Electronic Reporting and Recording of Controlled Drugs (formerly Pharmaceutical Drugs of Addiction System)	(a) National Health Service (b) Office for National Statistics 'Deaths Related to Drug Poisoning in England and Wales'
Mean follow-up duration	NI	NI	NI	NI	Median: 6.7 years per person (IQR: 3.7-8.4)	NI	NI
Patient follow-up and censoring definition	NI	NI	Until the start of next treatment episode, death, or after 12 months since termination of treatment, whichever came first	Until death; December 31, 2017; or 4 years from the last OAT episode ceasing	Until the start of next treatment episode, death, or end of follow-up, whichever came first	Until the start of next treatment episode, death, or December 31, 2017;	NI
Exposure definition	NI	NI	Time-varying with a 28-day grace period	Time-varying with a 7-day grace period	Time-varying with a 6-day grace period	Time-varying with a 7-day grace period	NI

Outcome definition (e.g., ICD-9/10, DSM-IV, etc.)	ICD-10	ICD-10	ICD-9 and ICD-10	ICD-10	ICD-10	ICD-10	ICD-10
Key inclusion and exclusion criteria	<p>Inclusion: All patients in the national OAT program who died between January 1, 2014 and December 31, 2015 during ongoing treatment or not more than 5 days after the last reported intake of OAT medication</p> <p>Exclusion: Patients who died more than 5 days after last reported intake of OAT medication and those whose OAT status was unknown at the time of death</p>	<p>Exclusion: Individuals whose death was caused by methadone or buprenorphine from a source other than an Opioid Treatment Program, including those prescribed as analgesics</p>	<p>Inclusion: Patients who were prescribed buprenorphine or methadone for treating opioid use disorder or opioid dependence, patients who were 15-64 years of age</p> <p>Exclusion: Patients who were prescribed buprenorphine or methadone for pain relief, Patients who received doses below the minimum expected for OST (i.e. < 20 mg/day methadone or < 4 mg/day buprenorphine), Patients younger than 15 or older than 64</p>	<p>Inclusion: Diagnosis of opioid dependence, received OAT between August 1, 2002 and December 31, 2017</p>	<p>Exclusion: Individuals who did not commence treatment, those in temporary programmes such as interstate patients, those in withdrawal programmes, and participants in clinical trials of buprenorphine because they were not necessarily given buprenorphine</p>	<p>Inclusion: All people prescribed OAT for the treatment of opioid dependence or opioid use disorder in the Australian state of New South Wales (NSW) between August 1, 2001 and September 30, 2018</p>	<p>Exclusion: Prescriptions for detoxification or pain management, including sublingual formulations of buprenorphine, buprenorphine patches, methadone tablets, and methadone indicated as cough suppressants</p>
Total number of patients	200	16434	5935	45664	32033	37764	NI
Number and % of treatment episodes with buprenorphine	NI	NI	6050 (38.8%)	16401 (35.9%)	29206 (40.9%)	55535 (52.4%) ^s	2602374 (13.1%)
Number and % of treatment episodes with methadone	NI	NI	9550 (61.2%)	29263 (64.1%)	42203 (59.1%)	60688 (57.3%) ^s	17333163 (86.9%)

Mean age of patients	48.9	At time of death: (a) 39 (for those who died during treatment) (b) 37 (for those who died while out of treatment)	NI	NI (However, median age given: 32)	NI	NI	NI
% of male patients	74%	At time of death: (a) 78.9% (for those who died during treatment) (b) 73.1% (for those who died while out of treatment)	68.81%	67.7%	NI	68.9%	NI
% of patients with any or specific psychiatric or mental health disorders	Psychiatric hospital admissions in past 5 years before death = 28% Benzodiazepine prescription in past 1 year before death = 43% Psychotropic medication prescription in past 1 year before death = 28% Previous non-fatal overdose = 30%	NI	Existing self-harm history = 1.47% Existing overdose history = 23.27% Alcohol problems = 17.99% Prison history = 5.64% Homeless history = 2.21%	Hospitalizations in past 12 months before cohort entry: - Self-harm: 11.1% - Mental health: 21.7% - Substance use disorder: 58.4%	NI	Non-drug mood disorder = 28.2% Self-harm / suicide attempt = 19.7% Psychiatric disorder = 11.4% Substance use disorder = 49.2%	NI
Exposure group	Methadone	Methadone	Buprenorphine	Methadone	Methadone	Buprenorphine	Methadone
Reference group	Buprenorphine	Buprenorphine	Methadone	Buprenorphine	Buprenorphine	Methadone	Buprenorphine
Specific outcome investigated	Drug-induced cause of death	Overdose deaths	Drug-related poisoning mortality	Fatal opioid overdose	Drug-related overdose deaths	Fatal opioid overdose	Deaths related to drug poisoning
Effect measure during maintenance treatment, after treatment discontinuation, or overall	In treatment	(a) In treatment (b) Diversion (c) Overall (in treatment + diversion)	(a) On treatment (first 4 weeks) (b) On treatment (4 weeks after initiation until end of treatment) (c) Off treatment (first 4 weeks) (d) Off treatment (4 weeks after	(a) In treatment (first 4 weeks) (b) In treatment (4 weeks after initiation until end of treatment) (c) Out of treatment (first 4 weeks)	(a) In treatment (first 4 weeks) (b) In treatment (4 weeks after initiation until end of treatment) (c) Out of treatment (first 4 weeks)	Age groups: (a) < 30 years (b) 30-39 years (c) 40-49 years (d) 50+ years Chronic disease:	Overall (in treatment + diversion)

			discontinuation until end of treatment)	(d) Out of treatment (4 weeks after discontinuation until end of treatment)	(d) Out of treatment (4 weeks after discontinuation until end of treatment)	(e) No evidence of target chronic disease (f) Circulatory disease (g) Kidney disease (h) Liver disease (i) Respiratory disease	
Number of buprenorphine-related deaths	82	(a) 0 (b) 2 (c) 2	(a) 1 (b) 4 (c) 8 (d) 6	(a) <= 5 (b) 62 (c) 57 (d) 308	(a) 2 (b) 29 (c) 18 (d) 125	(a) 9 (b) 23 (c) 17 (d) 11 (e) 34 (f) 12 (g) 8 (h) 6 (i) 13	57
Person-years for the buprenorphine group	8487	NI (All patients were assumed to have been in the study for 9 months [April 2006-December 2006])	(a) 334 (b) 2242 (c) 424 (d) 1878	(a) X# (b) 50835 (c) 3183 (d) 53079	(a) 2094.3 (b) 19841.9 (c) 1673.6 (d) 29565.3	(a) 11016 (b) 18229 (c) 12901 (d) 6195 (e) 35762 (f) 6213 (g) 1794 (h) 1445 (i) 7824	NI (Rate ratio calculated based on the number of prescriptions)
Number of methadone-related deaths	109	(a) 19 (b) 24 (c) 43	(a) 7 (b) 23 (c) 10 (d) 28	(a) 25 (b) 362 (c) 107 (d) 438	(a) 18 (b) 151 (c) 10 (d) 206	(a) 37 (b) 77 (c) 73 (d) 56 (e) 113 (f) 77 (g) 26 (h) 25 (i) 86	2366
Person-years for the methadone group	5707	NI (All patients were assumed to have been in the study for 9 months [April 2006-December 2006])	(a) 563 (b) 6924 (c) 620 (d) 3379	(a) 3603 (b) 207752 (c) 3985 (d) 95166	(a) 3343.9 (b) 88448.5 (c) 1835.5 (d) 43429.6	(a) 25533 (b) 47208 (c) 32794 (d) 14785 (e) 87342 (f) 16123	NI (Rate ratio calculated based on the number of prescriptions)

						(g) 4654 (h) 3811 (i) 21038	
Statistical model employed	Multilevel logistic regression	Pooling (to estimate rate ratio), table presented	Poisson regression	Generalized estimating equations	Poisson regression	Marginal structural models	Pooling using meta-analysis effect size calculator (to estimate rate ratio), table presented
Confounders included in the regression model	Sex, age, Charlson Comorbidity Index score, history of non-fatal overdose and psychiatric hospital admissions in previous 5 years, and OAT duration in years	NI	Sex; age; calendar year; comorbidity score; geographical region; benzodiazepine co-prescription; gabapentoid co-prescription; number of OST patients per GP practice; number of GPs prescribing per practice; and history recorded of self-harm, overdose poisoning, alcohol problems, imprisonment or homelessness	OAT status; sex; treatment; Aboriginal and/or Torres Strait Islander status, Index of Relative Socio-Economic Disadvantage; geographical remoteness; incarceration; hospitalizations in the previous 12 months (substance use disorder, self-harm, mental health episode); mental health ambulatory outpatient activity	Sex and age	Weight-adjusted for treatment selection bias using: Year, sex, geographical remoteness, Indigenous status, socio-economic disadvantage index, recency of: criminal charges, previous OAT history, most recent OAT, hospital admissions for respiratory, substance use, previous NFOD on OAT, prescriber preference Weight adjusted for censorship using:	NI

						Year, sex, geographical remoteness, indigeneity, socio-economic disadvantage index, previous OAT history, treatment and treatment × year interaction and recency of: incarceration, hospital admissions for mood and psychosis disorders, substance use and mental health ambulatory outpatient activity	
Techniques employed to control for confounding	Regression adjustments + Random intercepts for region included to correctly adjust the estimates for within-region correlations	NI	Propensity score technique - generated using inverse probability of treatment weights in order to balance the covariates between the two medication groups and improve model stability Inclusion of an interaction between treatment modality and age and comorbidity	Regression adjustments	Fractional polynomial regression to find optimal functions for continuous age variable (found no significant residual confounding of the methadone-buprenorphine association due to the grouping of the age variable) Rule-out method to establish how strong the	Marginal structural models that included inverse probability treatment and censorship weights	NI

			in the final adjusted models		residual confounding would have to be to explain the effect sizes (concluded that the associations are unlikely to be due to unmeasured confounding)		
Type of effect measure reported (HR, OR, or IRR)	Adjusted odds ratio	Crude rate ratio	Adjusted mortality incidence rate ratio (IPW adjusted + interactions)	Adjusted incidence rate ratios	Adjusted mortality rate ratio	Adjusted incidence rate ratios	Crude rate ratio
Estimate of association (95% CI)	1.25 (0.63-2.48)	(a) NA (b) 2.38 (0.56-10.05) (c) 4.25 (1.03-17.54)	(a) 0.08 (0.01-0.48) (b) 0.37 (0.17-0.79) (c) 0.78 (0.36-1.66) (d) 0.23 (0.12-0.48)	(a) 3.95 (0.89-17.51) (b) 1.43 (0.94-2.17) (c) 1.55 (0.94-2.55) (d) 0.82 (0.65-1.03)	(a) 4.88 (1.73-13.69) (b) 1.18 (0.89-1.56) (c) 0.50 (0.29-0.86) (d) 1.12 (0.96-1.31)	(a) 0.46 (0.17-1.26) (b) 0.61 (0.32-1.18) (c) 0.70 (0.30-1.64) (d) 0.49 (0.17-1.41) (e) 0.67 (0.38-1.17) (f) 0.27 (0.11-0.67) (g) 1.16 (0.31-4.36) (h) 0.59 (0.14-2.43) (i) 0.26 (0.07-0.94)	6.23 (4.79-8.10)

Abbreviations: NI = No Information; # = Output suppressed due to small death counts (≤ 5); \$ = Numbers as shown by the original study

Table S5. Assessment of risk of bias using ROBINS-I

Article	Bech et al. (2019)	Bell et al. (2009)	Hickman et al. (2018)	Jones et al. (2022)	Kimber et al. (2015)	Larney et al. (2023)	Marteau et al. (2015)
Bias due to confounding							
1.1. Is there potential for confounding of the effect of intervention in this study?	PY	Y	PY	PY	Y	PY	Y
1.2. Was the analysis based on splitting participants' follow up time according to intervention received? (If N/PN, go to 1.4-1.6; If Y/PY, go to 1.3)	N	N	Y	Y	Y	Y	N
1.3. Were intervention discontinuations or switches likely to be related to factors that are prognostic for the outcome?	NA	NA	PN	PN	PN	PN	NA
<i>Questions relating to BL confounding only</i>							
1.4. Did the authors use an appropriate analysis method that controlled for all the important confounding domains?	Y	N	PY	PY	PN	Y	N
1.5. If Y/PY to 1.4: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study?	PY	NA	PY	PY	PY	PY	NA
1.6. Did the authors control for any post-intervention variables that could have been affected by the intervention?	N	N	N	N	N	N	N
<i>Questions relating to BL and time-varying confounding</i>							
1.7. Did the authors use an appropriate analysis method that controlled for all the important confounding domains and for time-varying confounding?	N	N	PN	PN	PN	PY	N
1.8. If Y/PY to 1.7: Were confounding domains that were controlled for measured validly and reliably by the variables available in this study?	NA	NA	NA	NA	NA	PY	NA
Bias in selection of participants in the study							
2.1. Was selection of participants into the study (or into the analysis) based on participant characteristics observed after the start of intervention?	N	N	N	N	N	N	N
<i>If N/PN to 2.1, go to 2.4:</i>							
2.2. If Y/PY to 2.1: Were the post-intervention variables that influenced selection likely to be associated with intervention?	NA	NA	NA	NA	NA	NA	NA
2.3. If Y/PY to 2.2: Were the post-intervention variables that influenced selection likely to be influenced by the outcome or a cause of the outcome?	NA	NA	NA	NA	NA	NA	NA
2.4. Do start of follow-up and start of intervention coincide for most participants?	N	N	PY	PY	PY	PY	N
2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?	N	N	NA	NA	NA	NA	N
Bias in classification of interventions							

3.1. Were intervention groups clearly defined?	PY	PY	PY	PY	PY	PY	PY
3.2. Was the information used to define intervention groups recorded at the start of the intervention?	N	N	PY	PY	PY	PY	N
3.3. Could classification of intervention status have been affected by knowledge of the outcome or risk of the outcome?	N	N	N	N	PN	N	N
Bias due to deviations from intended intervention							
4.1. Were there deviations from the intended intervention beyond what would be expected in usual practice?	PN	PN	PN	PN	PN	PN	PN
4.2. If Y/PY to 4.1: Were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome?	NA	NA	NA	NA	NA	NA	NA
4.3. Were important co-interventions balanced across intervention groups?	NA	NA	NA	NA	NA	NA	NA
4.4. Was the intervention implemented successfully for most participants?	NA	NA	NA	NA	NA	NA	NA
4.5. Did study participants adhere to the assigned intervention regimen?	NA	NA	NA	NA	NA	NA	NA
4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis used to estimate the effect of starting and adhering to the intervention?	NA	NA	NA	NA	NA	NA	NA
Bias due to missing data							
5.1. Were outcome data available for all, or nearly all, participants?	PY	PY	N	PY	PY	PY	Y
5.2. Were participants excluded due to missing data on intervention status?	PY	PN	PN	PN	PN	PN	N
5.3. Were participants excluded due to missing data on other variables needed for the analysis?	N	N	PN	PN	PN	N	N
5.4. If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of participants and reasons for missing data similar across interventions?	PY	NA	Y	NA	NA	NA	NA
5.5. If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that results were robust to the presence of missing data?	PY	NA	PY	NA	NA	NA	NA
Bias in measurement of outcomes							
6.1. Could the outcome measure have been influenced by knowledge of the intervention received?	N	N	N	N	N	N	N
6.2. Were outcome assessors aware of the intervention received by study participants?	PN	PN	PN	PN	PN	PN	PN
6.3. Were the methods of outcome assessment comparable across intervention groups?	Y	Y	Y	Y	Y	Y	Y
6.4. Were any systematic errors in measurement of the outcome related to intervention received?	N	N	N	N	N	N	N
Bias in selection of the reported result							
Is the reported effect estimate likely to be selected, on the basis of the results, from...							
7.1. Multiple outcome measurements within the outcome domain?	N	N	N	N	N	N	N

7.2. Multiple analyses of the intervention-outcome relationship?	NI	NI	NI	NI	NI	NI	NI
7.3. Different Subgroups?	N	N	N	N	PN	N	N

Abbreviations: Y = Yes, PY = Possibly Yes, PN = Possibly No, N = No, NA = Not Applicable, NI = No Information